COVID-19 vaccine heavyweight Pfizer (NYSE:PFE) will soon provide data related to the fourth dose of its COVID-19 vaccine, according to Bloomberg.
The company and its partner BioNTech (Nasdaq: BNTX) are also developing an omicron-specific version of the vaccine.
Pfizer CEO Dr. Albert Bourla said that the data to be shared with FDA involve the fourth dose of its original COVID-19 vaccine and a new formulation intended to protect against multiple SARS-CoV-2 variants.
Data related to the omicron-specific version are not yet available.
Pfizer also said that clinical trial data involving children under 5 who received three doses of its COVID-19 vaccine would be available in April.
A small Israeli study summarized in Nature last month indicated that a fourth vaccine dose provides a modest increase in antibodies.